

**Kentucky Department for Medicaid Services**  
**Drug Management Review Advisory Board (DMRAB)**  
**Recommendations for Consideration**

The following chart provides a summary of the final decisions made by the Department for Medicaid Services (DMS) based on recommendations from the Drug Management Review Advisory Board (DMRAB) at the August 11, 2011 meeting.

**ProDUR Severity Level I Drug-to-Drug (DD) Interactions**

Interaction Description	DMRAB Recommendation	DMS Decision
SSRIs/MAOIs Furazolidone	Retain current PA requirements.	Claims will deny for PA; however, provider level override will be available.
Nelfinavir Ritonavir/Amiodarone	Retain current PA requirements.	Claims will deny for PA; however, provider level override will be available.
Selected Protease Inhibitors/Flecainide	Retain current PA requirements.	Claims will deny for PA; however, provider level override will be available.
Protease Inhibitors/Midazolam; Triazolam	Retain current PA requirements.	Claims will deny for PA; however, provider level override will be available.
Selected Protease Inhibitors/Propafenone	Retain current PA requirements.	Claims will deny for PA; however, provider level override will be available.
Selected Quinolones/Class IA and III Antiarrhythmics	Retain current PA requirements.	Claims will deny for PA; however, provider level override will be available.
Ergotamine Derivatives/Selected Macrolide Antibiotics	Retain current PA requirements.	Claims will deny for PA; however, provider level override will be available.
Protease Inhibitors/Pimozide	Retain current PA requirements.	Claims will deny for PA; however, provider level override will be available.
Protease Inhibitors/Ergot Derivatives	Retain current PA requirements.	Claims will deny for PA; however, provider level override will be available.
Carbamazepine/Monoamine Oxidase Inhibitors	Retain current PA requirements.	Claims will deny for PA; however, provider level override will be available.

Interaction Description	DMRAB Recommendation	DMS Decision
Ergotamine Derivatives/Delavirdine; Efavirenz	Retain current PA requirements.	Claims will deny for PA; however, provider level override will be available.
Protease Inhibitors/Rifampin; Rifapentine	Retain current PA requirements.	Claims will deny for PA; however, provider level override will be available.
Selected 5HT-1D Agonists/MAO Inhibitors	Retain current PA requirements.	Claims will deny for PA; however, provider level override will be available.
Nelfinavir; Ritonavir/Quinidine	Retain current PA requirements.	Claims will deny for PA; however, provider level override will be available.
Protease Inhibitors/Non-Sedating Antihistamines	Message only	This interaction will result in a message to the dispensing pharmacy.
Quinidine/Itraconazole; Voriconazole	Retain current PA requirements.	Claims will deny for PA; however, provider level override will be available.
Clarithromycin; Erythromycin/Quinupristin-Dalfopristin	Retain current PA requirements.	Claims will deny for PA; however, provider level override will be available.
Dofetilide/Verapamil	Retain current PA requirements.	Claims will deny for PA; however, provider level override will be available.
Dofetilide/Cimetidine	Retain current PA requirements.	Claims will deny for PA; however, provider level override will be available.
Dofetilide/Trimethoprim	Retain current PA requirements.	Claims will deny for PA; however, provider level override will be available.
Dofetilide/Itraconazole; Ketoconazole	Retain current PA requirements.	Claims will deny for PA; however, provider level override will be available.
Dofetilide/Prochlorperazine	Retain current PA requirements.	Claims will deny for PA; however, provider level override will be available.
Dofetilide/Megestrol	Retain current PA requirements.	Claims will deny for PA; however, provider level override will be available.
Dofetilide/Class I and III Antiarrhythmics	Retain current PA requirements.	Claims will deny for PA; however, provider level override will be available.
Selected HMG-CoA Reductase Inhibitors/Nefazodone	Retain current PA requirements.	Claims will deny for PA; however, provider level override will be available.

Interaction Description	DMRAB Recommendation	DMS Decision
Zidovudine/Ribavirin	Retain current PA requirements.	Claims will deny for PA; however, provider level override will be available.
Delavirdine/Rifampin; Rifabutin	Retain current PA requirements.	Claims will deny for PA; however, provider level override will be available.
Ketoconazole/Nevirapine	Retain current PA requirements.	Claims will deny for PA; however, provider level override will be available.
Selected HMG CoA Reductase Inhibitors/Protease Inhibitors	Retain current PA requirements.	Claims will deny for PA; however, provider level override will be available.
Ziprasidone/Selected Antiarrhythmics	Retain current PA requirements.	Claims will deny for PA; however, provider level override will be available.
Ziprasidone/Pimozide; Thioridazine	Retain current PA requirements.	Claims will deny for PA; however, provider level override will be available.
Ziprasidone/Moxifloxacin; Sparfloxacin	Retain current PA requirements.	Claims will deny for PA; however, provider level override will be available.
Ziprasidone/Selected Qt Prolongating Agents	Retain current PA requirements.	Claims will deny for PA; however, provider level override will be available.
Zidovudine/Doxorubicin	Retain current PA requirements.	Claims will deny for PA; however, provider level override will be available.
Dofetilide/Hydrochlorothiazide	Retain current PA requirements.	Claims will deny for PA; however, provider level override will be available.
Eletriptan/Selected Macrolide Antibiotics	Retain current PA requirements.	Claims will deny for PA; however, provider level override will be available.
Eletriptan/Itraconazole; Ketoconazole	Retain current PA requirements.	Claims will deny for PA; however, provider level override will be available.
Eletriptan/Selected Protease Inhibitors	Retain current PA requirements.	Claims will deny for PA; however, provider level override will be available.
Ergot Alkaloid Derivatives/Telithromycin	Retain current PA requirements.	Claims will deny for PA; however, provider level override will be available.
Selected HMG-CoA Reductase Inhibitors/Telithromycin	Retain current PA requirements.	Claims will deny for PA; however, provider level override will be available.

Interaction Description	DMRAB Recommendation	DMS Decision
Selected Anticonvulsants/Telithromycin	Retain current PA requirements.	Claims will deny for PA; however, provider level override will be available.
Delavirdine/Carbamazepine; Phenobarbital; Phenytoin	Retain current PA requirements.	Claims will deny for PA; however, provider level override will be available.
Ergot Alkaloids/Voriconazole	Retain current PA requirements.	Claims will deny for PA; however, provider level override will be available.
Flecainide/Lumefantrine	Retain current PA requirements.	Claims will deny for PA; however, provider level override will be available.
Ergotamine Derivatives/Itraconazole; Ketoconazole	Retain current PA requirements.	Claims will deny for PA; however, provider level override will be available.
Eletriptan/Nefazodone	Retain current PA requirements.	Claims will deny for PA; however, provider level override will be available.
Itraconazole; Ketoconazole/Isoniazid	Retain current PA requirements.	Claims will deny for PA; however, provider level override will be available.
Vardenafil/Indinavir; Ritonavir	Retain current PA requirements.	Claims will deny for PA; however, provider level override will be available.
Vardenafil/Itraconazole; Ketoconazole	Retain current PA requirements.	Claims will deny for PA; however, provider level override will be available.
Vardenafil/Alpha-Blockers	Retain current PA requirements.	Claims will deny for PA; however, provider level override will be available.
Vardenafil/Class IA and III Antiarrhythmics	Retain current PA requirements.	Claims will deny for PA; however, provider level override will be available.
Atazanavir/Proton Pump Inhibitors	Retain current PA requirements.	Claims will deny for PA; however, provider level override will be available.
Atazanavir/Indinavir	Retain current PA requirements.	Claims will deny for PA; however, provider level override will be available.
Delavirdine/Amprenavir; Fosamprenavir	Retain current PA requirements.	Claims will deny for PA; however, provider level override will be available.
Tadalafil/Alpha-Blockers	Retain current PA requirements.	Claims will deny for PA; however, provider level override will be available.

Interaction Description	DMRAB Recommendation	DMS Decision
Class IA and III Antiarrhythmics/Telithromycin	Retain current PA requirements.	Claims will deny for PA; however, provider level override will be available.
Efavirenz/Voriconazole	Retain current PA requirements.	Claims will deny for PA; however, provider level override will be available.
Nelfinavir; Ritonavir/Eplerenone	Retain current PA requirements.	Claims will deny for PA; however, provider level override will be available.
Clarithromycin; Troleandomycin/Eplerenone	Retain current PA requirements.	Claims will deny for PA; however, provider level override will be available.
Class IA and III Antiarrhythmics/Ibutilide	Retain current PA requirements.	Claims will deny for PA; however, provider level override will be available.
Atazanavir/Irinotecan	Retain current PA requirements.	Claims will deny for PA; however, provider level override will be available.
Amiodarone/Agalsidase	Retain current PA requirements.	Claims will deny for PA; however, provider level override will be available.
Cyclosporine/Rosuvastatin	Retain current PA requirements.	Claims will deny for PA; however, provider level override will be available.
Zalcitabine/Lamivudine	Retain current PA requirements.	Claims will deny for PA; however, provider level override will be available.
MAOIs/Atomoxetine	Retain current PA requirements.	Claims will deny for PA; however, provider level override will be available.
Itraconazole; Ketoconazole/Eplerenone	Retain current PA requirements.	Claims will deny for PA; however, provider level override will be available.
Protease Inhibitors/Artemether; Lumefantrine	Retain current PA requirements.	Claims will deny for PA; however, provider level override will be available.
Cimetidine/Artemether; Lumefantrine	Retain current PA requirements.	Claims will deny for PA; however, provider level override will be available.
Carbamazepine/Voriconazole	Retain current PA requirements.	Claims will deny for PA; however, provider level override will be available.
Delavirdine/Lovastatin; Simvastatin	Retain current PA requirements.	Claims will deny for PA; however, provider level override will be available.

Interaction Description	DMRAB Recommendation	DMS Decision
Delavirdine/Pimozide	Retain current PA requirements.	Claims will deny for PA; however, provider level override will be available.
Delavirdine/Alprazolam; Midazolam; Triazolam	Retain current PA requirements.	Claims will deny for PA; however, provider level override will be available.
Cyclosporine/Tacrolimus	Retain current PA requirements.	Claims will deny for PA; however, provider level override will be available.
Telithromycin/Rifampin	Retain current PA requirements.	Claims will deny for PA; however, provider level override will be available.
Cyclosporine/Bosentan	Retain current PA requirements.	Claims will deny for PA; however, provider level override will be available.
Zidovudine/Stavudine	Retain current PA requirements.	Claims will deny for PA; however, provider level override will be available.
Carbamazepine/Nefazodone	Retain current PA requirements.	Claims will deny for PA; however, provider level override will be available.
Ketoconazole; Voriconazole/Sirolimus	Retain current PA requirements.	Claims will deny for PA; however, provider level override will be available.
Zileuton/Pimozide	Retain current PA requirements.	Claims will deny for PA; however, provider level override will be available.
MAOIs /Entacapone; Tolcapone	Remove PA; pharmacy level override	Claims will deny for PA; however, provider level override will be available.
Efavirenz/Midazolam; Triazolam	Retain current PA requirements.	Claims will deny for PA; however, provider level override will be available.
Delavirdine; Efavirenz/Astemizole; Terfenadine	Retain current PA requirements.	Claims will deny for PA; however, provider level override will be available.
Nitrates/CGMP Specific PDE Type-5 Inhibitors	Retain current PA requirements.	Claims will deny for PA; however, provider level override will be available.
Class I and III Antiarrhythmics/Pimozide	Retain current PA requirements.	Claims will deny for PA; however, provider level override will be available.
Ergot Derivatives/Saquinavir Base	Retain current PA requirements.	Claims will deny for PA; however, provider level override will be available.

Interaction Description	DMRAB Recommendation	DMS Decision
Class I and III Antiarrhythmics/Halofantrine	Retain current PA requirements.	Claims will deny for PA; however, provider level override will be available.
MAOIs/Sibutramine	Retain current PA requirements.	Claims will deny for PA; however, provider level override will be available.
MAOIs /Bupropion	Retain current PA requirements.	Claims will deny for PA; however, provider level override will be available.
MAOIs /Apraclonidine; Brimonidine	Retain current PA requirements.	Claims will deny for PA; however, provider level override will be available.
Ergotamines; Methysergide/5ht-1d Agonists	Retain current PA requirements.	Claims will deny for PA; however, provider level override will be available.
Select HMG-CoA Reductase Inhibitors/Selected Azoles	Retain current PA requirements.	Claims will deny for PA; however, provider level override will be available.
Monoamine Oxidase Inhibitors; Furazolidone/Buspirone	Retain current PA requirements.	Claims will deny for PA; however, provider level override will be available.
MAOIs; Furazolidone/Levodopa	Retain current PA requirements.	Claims will deny for PA; however, provider level override will be available.
MAOIs; Furazolidone/Meperidine;Dextromethorphan	Retain current PA requirements.	Claims will deny for PA; however, provider level override will be available.
MAOIs; Furazolidone/Tri;Tetracyclic Compounds	Retain current PA requirements.	Claims will deny for PA; however, provider level override will be available.
MAOIs; Furazolidone/Sympathomimetics	Retain current PA requirements.	Claims will deny for PA; however, provider level override will be available.

**Potential New/Updated Edits**

Potential New/Updated Edit	DMRAB Recommendation	DMS Decision
Narcotic Combination Edit	Tabled until a specific list of diagnoses can be developed.	Agenda item will be brought back to the next meeting.